Benzinga | Apr 6, 2021 06:13AM EDT

Credit Suisse Initiates Coverage On Prometheus Biosciences with Outperform Rating, Announces Price Target of $30

Credit Suisse analyst Martin Auster initiates coverage on Prometheus Biosciences (NASDAQ:RXDX) with a Outperform rating and announces Price Target of $30.